BioCentury | Apr 21, 2016
Product R&D

A1M for preeclampsia

...the disease rather than their consequences." Cooper was CEO and founder of preeclampsia diagnostic company Carmenta Bioscience Inc....
BioCentury | Jun 8, 2015
Company News

Carmenta, Progenity deal

...Progenity acquired Carmenta for an undisclosed sum. Carmenta is developing risk assessment and confirmatory diagnostic tests...
...Progenity is a CLIA-accredited and CAP-certified laboratory specializing in women’s health and pediatric genetic testing. Carmenta Bioscience Inc....
BioCentury | Oct 16, 2014
Targets & Mechanisms

Alnylam interrupts preeclampsia

...the RNAi age? "These are really exciting data," said Matthew Cooper, founder and CEO of Carmenta Bioscience Inc....
...the disease, inducing beneficial structural changes in the placenta and improving outcomes for the fetuses. Carmenta...
...and Institutions Mentioned Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY), Cambridge, Mass. American Heart Association , Dallas, Texas Carmenta Bioscience Inc....
BioCentury | Aug 18, 2014
Emerging Company Profile

GestVision: Urine for preeclampsia

...developing a panel of four peptide markers but has not disclosed the test's development status. Carmenta Bioscience Inc....
...enable the company to manufacture the test for the international trial. Companies and Institutions Mentioned Carmenta Bioscience Inc....
BioCentury | Aug 7, 2014
Cover Story

Dyeing to diagnose preeclampsia

...in addition to those criteria or instead of them. Matthew Cooper, founder and CEO of Carmenta Bioscience Inc....
...that kind of diagnostic, so it's good to see that other researchers are getting involved." Carmenta...
...is basically a blood pressure check and the indication is underdiagnosed." Thus, the two diagnostic approaches-Carmenta's...
BioCentury | Aug 7, 2014
Distillery Techniques

Technology: Assays & screens

...biomarker soluble endoglin (CD105; ENG) in serum and urine, in pivotal trials to diagnose preeclampsia. Carmenta Bioscience Inc....
BioCentury | Mar 27, 2014
Strategy

Teaching translation

...path. We identify hurdles and address them," said Egeler. Matthew Cooper, founder and CEO of Carmenta Bioscience Inc....
...provided by the advisers, which ranges from venture funding and patent strategy to product development. Carmenta...
...Published online March 27, 2014 Companies and Institutions Mentioned Amgen Inc. (NASDAQ:AMGN), Thousand Oaks, Calif. Carmenta Bioscience Inc....
BioCentury | Sep 23, 2013
Emerging Company Profile

Carmenta: Preempting preeclampsia

...of symptoms that do not reliably differentiate it from other conditions, thereby delaying treatment decisions. Carmenta Bioscience Inc....
...at Carmenta narrowed the original panel of markers to six that Cooper declined to disclose. Carmenta...
...those symptoms, such as gestational diabetes, gestational hypertension and chronic hypertension," Cooper said. In 2012, Carmenta...
BioCentury | Aug 12, 2013
Financial News

Carmenta completes venture financing

Carmenta Bioscience Inc. , Palo Alto, Calif. Business: Diagnostic Date completed: 8/8/13 Type: Venture financing Raised: $2 million WIR Staff Diagnostic...
BioCentury | Aug 12, 2013
Company News

Carmenta board of directors update

Carmenta BioScience Inc. , Palo Alto, Calif. Business: Diagnostic Appointed: Camille Samuels WIR Staff Diagnostic...
Items per page:
1 - 10 of 11
BioCentury | Apr 21, 2016
Product R&D

A1M for preeclampsia

...the disease rather than their consequences." Cooper was CEO and founder of preeclampsia diagnostic company Carmenta Bioscience Inc....
BioCentury | Jun 8, 2015
Company News

Carmenta, Progenity deal

...Progenity acquired Carmenta for an undisclosed sum. Carmenta is developing risk assessment and confirmatory diagnostic tests...
...Progenity is a CLIA-accredited and CAP-certified laboratory specializing in women’s health and pediatric genetic testing. Carmenta Bioscience Inc....
BioCentury | Oct 16, 2014
Targets & Mechanisms

Alnylam interrupts preeclampsia

...the RNAi age? "These are really exciting data," said Matthew Cooper, founder and CEO of Carmenta Bioscience Inc....
...the disease, inducing beneficial structural changes in the placenta and improving outcomes for the fetuses. Carmenta...
...and Institutions Mentioned Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY), Cambridge, Mass. American Heart Association , Dallas, Texas Carmenta Bioscience Inc....
BioCentury | Aug 18, 2014
Emerging Company Profile

GestVision: Urine for preeclampsia

...developing a panel of four peptide markers but has not disclosed the test's development status. Carmenta Bioscience Inc....
...enable the company to manufacture the test for the international trial. Companies and Institutions Mentioned Carmenta Bioscience Inc....
BioCentury | Aug 7, 2014
Cover Story

Dyeing to diagnose preeclampsia

...in addition to those criteria or instead of them. Matthew Cooper, founder and CEO of Carmenta Bioscience Inc....
...that kind of diagnostic, so it's good to see that other researchers are getting involved." Carmenta...
...is basically a blood pressure check and the indication is underdiagnosed." Thus, the two diagnostic approaches-Carmenta's...
BioCentury | Aug 7, 2014
Distillery Techniques

Technology: Assays & screens

...biomarker soluble endoglin (CD105; ENG) in serum and urine, in pivotal trials to diagnose preeclampsia. Carmenta Bioscience Inc....
BioCentury | Mar 27, 2014
Strategy

Teaching translation

...path. We identify hurdles and address them," said Egeler. Matthew Cooper, founder and CEO of Carmenta Bioscience Inc....
...provided by the advisers, which ranges from venture funding and patent strategy to product development. Carmenta...
...Published online March 27, 2014 Companies and Institutions Mentioned Amgen Inc. (NASDAQ:AMGN), Thousand Oaks, Calif. Carmenta Bioscience Inc....
BioCentury | Sep 23, 2013
Emerging Company Profile

Carmenta: Preempting preeclampsia

...of symptoms that do not reliably differentiate it from other conditions, thereby delaying treatment decisions. Carmenta Bioscience Inc....
...at Carmenta narrowed the original panel of markers to six that Cooper declined to disclose. Carmenta...
...those symptoms, such as gestational diabetes, gestational hypertension and chronic hypertension," Cooper said. In 2012, Carmenta...
BioCentury | Aug 12, 2013
Financial News

Carmenta completes venture financing

Carmenta Bioscience Inc. , Palo Alto, Calif. Business: Diagnostic Date completed: 8/8/13 Type: Venture financing Raised: $2 million WIR Staff Diagnostic...
BioCentury | Aug 12, 2013
Company News

Carmenta board of directors update

Carmenta BioScience Inc. , Palo Alto, Calif. Business: Diagnostic Appointed: Camille Samuels WIR Staff Diagnostic...
Items per page:
1 - 10 of 11